According to Taipei Times reporter Kuo Hong-hui, Sinh Da Pharma (1720) reported record-high net profit for the first three quarters of 2026, with full-year earnings expected to reach historical highs. The stock jumped to 55.9 NT$ today (November 13), up nearly 2%. However, a 10% capital expansion from stock dividends may limit earnings-per-share growth.

Domestically, the company launched five new pharmaceutical products in 2026. Its bladder overactivity treatment gained a successful patent challenge verdict and is expected to launch commercially in Q1 2027. Additionally, a licensed gout treatment drug received regulatory approval and is entering health insurance pricing negotiations. Internationally, Sinh Da is expanding operations in Japan, with three drugs currently generating steady revenue and five new candidates under development.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.